Industry News
Pharmaceutical Industry News
As self-administered therapies…
As self-administered therapies grow, pharma companies are rethinking how onboarding, training and engagement work together.
In her inaugural earnings call as…
In her inaugural earnings call as the new CEO of Sanofi, Belén Garijo—until recently head honcho at Germany’s Merck KGaA—laid out her ambitions for the French pharma juggernaut, plainly addressing the issues that have tripped
Alnylam’s stock price plummeted…
Alnylam’s stock price plummeted as much as 29% Thursday morning after disappointing Amvuttra sales and a lowered full-year forecast triggered fresh concerns over the ATTR franchise.
In MrBeast’s new “I Helped 100…
In MrBeast's new “I Helped 100 Kids Fight Cancer" YouTube video, Amgen spread its oncology research messaging to a new audience of the channel's over 500 million subscribers.
Worldwide sales of Regeneron and…
Worldwide sales of Regeneron and Sanofi's Dupixent were up again in the second quarter, reaching $6 billion for the first time thanks to a 38% increase.
Despite Robert F. Kennedy Jr….
Despite Robert F. Kennedy Jr. ultimately agreeing to divest referral fees tied to litigation around Merck & Co.’s HPV vaccine Gardasil to win confirmation as Health and Human Services secretary last year, a quartet of
Investors awaiting Bristol Myers…
Investors awaiting Bristol Myers Squibb’s key Alzheimer’s psychosis readout for Cobenfy and atrial fibrillation data for milvexian will have to wait a little longer.
The FDA has rebuked Viatris for a…
The FDA has rebuked Viatris for a direct-to-consumer video that allegedly misled viewers about a cystic fibrosis inhaler.
Eli Lilly has doubled down on its…
Eli Lilly has doubled down on its partnership with CDMO Resilience as the companies plan to invest $750 million to increase production of Lilly’s KwikPen injectable device for its diabetes and obesity medicines Mounjaro and
In pharma, a wall doesn’t just…
In pharma, a wall doesn't just cost money, it stands between a brand and its outcome.
With increased sales of its newer…
With increased sales of its newer drugs compensating for declining revenues from its multiple sclerosis portfolio, Biogen finally is positioned once again for a “growth story,” CEO Chris Viehbacher said Wednesday during the company’s second
As Teva proceeds down the more…
As Teva proceeds down the more muted growth path that it telegraphed early this year, the generics and innovative medicines hybrid isn’t letting a little sales slump affect its confidence in a budding portfolio of
A favorable regulatory resolution…
A favorable regulatory resolution with federal health authorities is clearing the way for Incyte’s Opzelura cream to reach blockbuster land ahead of schedule.
Hoffman wanted to be a part of the…
Hoffman wanted to be a part of the decision-making that "truly affects people" in healthcare, sparking a pivot from PR to pharma marketing, where she can use her natural creative and strategic lens to maximize
Manufacturers often focus on the…
Manufacturers often focus on the costs of hub transition. The bigger risk is inertia. Here's what staying fragmented is costing you.
The U.K. pharma marketing watchdog…
The U.K. pharma marketing watchdog has slammed AGB Pharma for misleadingly implying a lack of fertility considerations for its melatonin medicine, Adaflex.
Trump Will End Subsidies for Medicare Drug Premiums
Millions of older Americans could pay more for their prescription drug coverage next year.
What to Do if Your Estrogen Patch Is Out of Stock
Some hormone therapy patches are still in short supply. Here’s what experts recommend to avoid missing a dose.
The Considered+AI is an AI-native…
The Considered+AI is an AI-native agency that's been rooted in generative AI tools since its start in 2021.
Even though Hengrui Pharma has…
Even though Hengrui Pharma has resolved the manufacturing problems cited in a recent FDA complete response letter, a second citation stands in the way of the company and its partner Elevar Therapeutics’ fourth attempt at